Gordon Holt

Gordon Holt's work experience starts with their current position as the Vice President of Translational R&D at LifeSprout, Inc. since 2022. Previously, from 2009 to 2019, they served as the Chief Science Officer at NorthShore Bio / Lux Bio Group, where they managed the scientific, IP, financial, and business development aspects of commercializing a novel nanopore technology for genome-scale DNA & RNA sequencing. Prior to that, from 2004 to 2009, Gordon worked as the Director of Biotech Business Development at Intel Corporation, where they led the development of various innovative products, including a programmable electrical synthesis and molecular detection chip for DNA and protein microarrays, biothreat detection, and diagnostics. Before Intel, from 1994 to 2004, they held the role of Director of Science Development at Oxford GlycoSciences, overseeing drug target and biomarker discovery and validation programs using proteomics and genomics. Gordon's earliest work experience was as a Senior Staff Fellow at the National Institutes of Health (NIH) in the Intramural Research Program (IRP) from 1988 to 1994, where they focused on rare genetic diseases, viral and parasitic infectivity, and cancer cell metastasis mechanisms.

Gordon Holt completed their undergraduate studies at Washington University in St. Louis from 1978 to 1982, earning a Bachelor of Arts degree in Chemistry. Following that, they pursued their postgraduate education at The Johns Hopkins University School of Medicine, where they obtained their Ph.D. degree in the fields of Biochemistry, Cell Biology, and Glycobiology. No specific start or end years were provided for their time at The Johns Hopkins University School of Medicine.